Fig. 1 · Structure

Documents & Downloads

MDL 28170

Cat. No. A15303 CAS 88191-84-8

Calpain Inhibitor III

MDL 28170 is a cell permeable selective inhibitor of Calpain 1, a Ca2+-dependent cysteine protease which has been implicated in apoptosis of immune cells as well as neuronal cells.

In Stock

Publications for MDL 28170

1 publication citing this product

  1. Barker BS, .et al. , Neuroscience, 2019, Nov 26. pii: S0306-4522(19)30796-1 PMID: 31783100

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In human retinal endothelial cells, MDL 28170 at 10 nM improved capillary network organization while producing only partial inhibition of cellular calpain activity (~30–35%). A separate calpastatin-peptide comparator produced similar effects, supporting a calpain-related mechanism without establishing exclusive target selectivity. These cellular findings do not provide a purified-enzyme potency value. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

MDL 28170 Research Summary

This section summarizes 1 in vitro study and 4 in vivo studies of MDL 28170 from 3 published references. In vivo models include young adult male CF-1 mice with controlled cortical impact; adult male Long–Evans rats, unilateral optic nerve stretch.

MDL 28170 In Vitro Studies

In a collagen-I overlay assay, 10 nM MDL 28170 increased retinal endothelial cord length and polygon formation and reduced blind ends versus vehicle. Higher concentrations were less effective or inhibitory, so the response should not be generalized as increasing with concentration. [1]

Concentration-dependent modulation of retinal endothelial morphogenesis

Cell-based study · Human retinal microvascular endothelial cells, passages 3–7, collagen-I overlay capillary morphogenesis assay [1]

MDL 28170 at 10 nM improved cord organization and reduced blind ends compared with vehicle. Calpastatin peptide gave similar effects. A cellular activity assay linked the effective concentration to partial calpain inhibition; higher concentrations gave less improvement or inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cord length, closed polygon formation and blind ends during collagen-I overlay morphogenesisDirection and statistical comparison Increased cord length and polygons; reduced blind ends[1]
Calpain substrate-cleaving activity in live retinal endothelial cells at the morphogenesis-effective concentrationReported inhibition ~30–35% at 10 nM MDL 28170[1]
Closed polygons per microscopic field across MDL 28170 concentrationsConcentration dependence Maximal improvement at 10 nM; lower and higher concentrations less effective or inhibitory[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM MDL 28170; concentration-response experiment also tested lower and higher concentrations
Exposure duration
Overnight inhibitor pretreatment; 4 h morphogenesis after collagen-I overlay
Method
Inhibitor added before and with collagen-I overlay; actin/tubulin imaging and ImageJ network measurements; separate cellular calpain activity readout.
Vehicle
Vehicle control used; composition not specified in the retrieved main-text methods
Co-treatment
No combination treatment: 200 nM calpastatin peptide was a separate comparator.
Reported limits
Independent biological-replicate/donor meaning of n and exact vehicle composition not specified in main text.
Methods and source locations

Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170

Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.

Methods 2.4–2.6; Results 3.4; Fig. 4A–C,E–F and caption

Cord length, closed polygon formation and blind ends during collagen-I overlay morphogenesis: Fig. 4B: p<0.001, n=21 for each group, as captioned; the paper does not define n as independent donors. Comparators: vehicle and 200 nM calpastatin peptide. — Methods 2.4–2.6; Results 3.4; Fig. 4A–C,E–F and caption

Calpain substrate-cleaving activity in live retinal endothelial cells at the morphogenesis-effective concentration: Fluorometric CMAC substrate assay; Fig. 4F and Results 3.4. This is a cellular response, not a purified-enzyme Ki or IC50. — Methods 2.4–2.6; Results 3.4; Fig. 4A–C,E–F and caption

Closed polygons per microscopic field across MDL 28170 concentrations: Fig. 4E: 10 nM differs from vehicle and 100 nM, p<0.001; n≥15 per group as captioned. No exact polygon count inferred from graph. — Methods 2.4–2.6; Results 3.4; Fig. 4A–C,E–F and caption

MDL 28170 In Vivo Studies

In male CF-1 mice after controlled cortical impact, an extended MDL-28170 regimen reduced the calpain-specific spectrin fragment SBDP145 at 24 h by 40% in hippocampus and 44% in cortex; abbreviated treatment did not. A separate histological experiment using the extended regimen found no reduction in neurodegeneration at 48 h. Thus, biochemical protection did not establish reduced tissue damage in this model. [2]

Short-duration intravenous MDL-28170 failed to significantly preserve retrograde axonal transport four days after optic nerve stretch in male rats. The authors could not establish sufficient target engagement in optic nerve axons and reported transient bradycardia and respiratory difficulty during the initial bolus in approximately 15–20% of rats. These findings limit generalization across neural injury models. [3]

In mouse oxygen-induced retinopathy, daily intraperitoneal MDL 28170 at 0.25 mg/kg improved vascular coverage and reduced retinal hypoxic area versus vehicle. Doses of 0.5 mg/kg and higher inhibited neovascular regrowth, indicating a model-specific dose window rather than a uniform pro-vascular effect. [1]

Regimen-dependent reduction of post-traumatic spectrin breakdown

Animal study · Young adult male CF-1 mice, controlled cortical impact; ipsilateral cortex and hippocampus [2]

The four-dose regimen reduced calpain-specific SBDP145 at 24 h, whereas the two-dose regimen failed to reduce it. Sham and injured vehicle groups were included; biochemical protection did not establish overall tissue protection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Calpain-specific 145-kDa alpha-spectrin breakdown product in ipsilateral hippocampus and cortex at 24 hReduction versus injured vehicle 40% in hippocampus; 44% in cortex[2]
SBDP145 after abbreviated two-dose treatment at 24 hTreatment effect No reduction in either region[2]

Conditions shared by the study groups

Route
IV then IP
Vehicle
Polyethylene glycol 300:ethanol, 9:1
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Extended four-dose regimen
20 mg/kg IV at 15 min after injury, followed by 40 mg/kg IP at 45 min, 2 h 45 min and 4 h 45 min
Injured vehicle; non-injured shamReduced SBDP145 at 24 h in both regions[2]
Abbreviated two-dose regimen
20 mg/kg IV at 15 min; 40 mg/kg IP at 45 min after injury
Injured vehicle; non-injured shamNo reduction in SBDP145 at 24 h[2]
Extended four-dose regimen
Model: Young adult male CF-1 mice, controlled cortical impact; ipsilateral cortex and hippocampus
Frequency: Four administrations
Treatment course: 15 min to 4 h 45 min after injury
Abbreviated two-dose regimen
Model: Young adult male CF-1 mice, controlled cortical impact; ipsilateral cortex and hippocampus
Frequency: Two administrations
Treatment course: First 45 min after injury
Methods and source locations

Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170

Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.

Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption

Calpain-specific 145-kDa alpha-spectrin breakdown product in ipsilateral hippocampus and cortex at 24 h: Western immunoblotting of SBDP145; n=8 mice/group; displayed mean ± standard error; p<0.05 versus vehicle by Student–Newman–Keuls after ANOVA. — Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption

SBDP145 after abbreviated two-dose treatment at 24 h: 20 mg/kg IV at 15 min plus 40 mg/kg IP at 45 min; n=8 mice/group; Fig. 2A. — Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption

Extended four-dose regimen · Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption

Abbreviated two-dose regimen · Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption

No reduction of histological neurodegeneration at 48 h

Animal study · Young adult male CF-1 mice with controlled cortical impact [2]

The extended regimen that reduced spectrin breakdown in the separate 24-h experiment did not reduce total histological neurodegeneration at 48 h. The endpoint combined silver-stained tissue and contusion cavity volume.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Silver-stained tissue plus cortical contusion lesion, normalized to contralateral hemisphere volume, at 48 hTreatment effect No reduction versus injured vehicle[2]

Conditions shared by the study groups

Route
IV then IP
Frequency
Four administrations
Treatment course
15 min to 4 h 45 min after injury
Vehicle
Polyethylene glycol 300:ethanol, 9:1
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Extended regimen, histological endpoint
20 mg/kg IV at 15 min after injury, followed by 40 mg/kg IP at 45 min, 2 h 45 min and 4 h 45 min
Injured vehicle; sham (including four historical shams)No reduction in total neurodegeneration at 48 h[2]
Extended regimen, histological endpoint
Model: Male CF-1 mice, controlled cortical impact
Methods and source locations

Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170

Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.

Methods: Silver staining, MDL-28170 preparation, Statistical analysis; Results: Effect of MDL-28170 on post-traumatic neurodegeneration; Fig. 4 and caption

Silver-stained tissue plus cortical contusion lesion, normalized to contralateral hemisphere volume, at 48 h: de Olmos aminocupric silver staining; blinded image analysis; injured vehicle and MDL groups n=8 each; sham n=6. Four sham animals were historical controls. — Methods: Silver staining, MDL-28170 preparation, Statistical analysis; Results: Effect of MDL-28170 on post-traumatic neurodegeneration; Fig. 4 and caption

Extended regimen, histological endpoint · Methods: Silver staining, MDL-28170 preparation, Statistical analysis; Results: Effect of MDL-28170 on post-traumatic neurodegeneration; Fig. 4 and caption

Short-duration treatment failed to preserve axonal transport

Animal study · Adult male Long–Evans rats (300–400 g), unilateral optic nerve stretch [3]

Short-duration intravenous MDL-28170 did not significantly preserve retrograde Fluorogold transport at four days. Contralateral uninjured eyes served as within-animal controls. This negative result is specific to this isolated axonal-injury model and regimen.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Decrease in Fluorogold-labeled retinal ganglion cells, injured versus contralateral uninjured retina, at four daysMean ± standard deviation Vehicle: 66±30%; MDL-28170: 64±25%[3]

Conditions shared by the study groups

Route
Intravenous
Frequency
One bolus then continuous infusion
Treatment course
Bolus over 10–15 min; infusion initiated immediately after bolus and continued 2.5 h; injury 30 min after bolus completion
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Short-duration IV pretreatment
30 mg/kg bolus; 15 mg/kg/h infusion
Equal-volume DMSO; contralateral uninjured retinaNo significant preservation of retrograde transport at four days; p=0.93 versus injured vehicle[3]
Short-duration IV pretreatment
Model: Adult male Long–Evans rat optic nerve stretch
Reported limits: Target engagement in optic nerve axons uncertain; transient cardiorespiratory adverse observations reported.
Methods and source locations

Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170

Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.

Methods: Rat optic nerve stretch, MDL-28170 therapy, Assessment of FG axonal transport in RGCs, Statistical analysis; Results: FG-cells in the retina; Fig. 2 and caption; Discussion: Limitations

Decrease in Fluorogold-labeled retinal ganglion cells, injured versus contralateral uninjured retina, at four days: Fluorogold retrograde transport with TUJ1 immunostaining and blinded counting; vehicle n=5 animals, MDL n=7; preplanned injured-group comparison p=0.93. — Methods: Rat optic nerve stretch, MDL-28170 therapy, Assessment of FG axonal transport in RGCs, Statistical analysis; Results: FG-cells in the retina; Fig. 2 and caption; Discussion: Limitations

Short-duration IV pretreatment · Methods: Rat optic nerve stretch, MDL-28170 therapy, Assessment of FG axonal transport in RGCs, Statistical analysis; Results: FG-cells in the retina; Fig. 2 and caption; Discussion: Limitations

Moderate dosing improved retinal revascularization; higher doses inhibited regrowth

Animal study · C57BL/6 mouse pups, oxygen-induced ischemic retinopathy [1]

Daily MDL 28170 at 0.25 mg/kg improved retinal vascular coverage and reduced hypoxic area versus vehicle. Doses of 0.5 mg/kg and higher inhibited neovascular regrowth, establishing a non-monotonic response in this model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Avascular retinal area at P17Direction versus vehicle Reduced with 0.25 mg/kg once daily[1]
Hypoxic retinal area at P17 and P21Direction versus time-matched vehicle Reduced with 0.25 mg/kg once daily[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Vehicle
Not specified in retrieved main text
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Moderate-dose MDL 28170
0.25 mg/kg
Vehicle; separate PD150606 and ALLN comparator groupsImproved vascular coverage at P17 and reduced hypoxic area at P17/P21[1]
Higher-dose limitation
0.5 mg/kg and higher
Vehicle and 0.25 mg/kg groupInhibited neovascular regrowth rather than improving it[1]
Moderate-dose MDL 28170
Model: C57BL/6 mouse pups, oxygen-induced retinopathy
Treatment course: P12–P16 for P17 endpoint; P12–P20 for P21 endpoint
Reported limits: Pup sex and vehicle composition not specified.
Higher-dose limitation
Model: C57BL/6 mouse pups, oxygen-induced retinopathy
Treatment course: P12–P16; retinal vascular coverage assessed at P17
Reported limits: No exact effect size extracted from dose curve.
Methods and source locations

Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170

Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.

Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption

Avascular retinal area at P17: Whole-mount TRITC-lectin imaging; Fig. 2B: p<0.05, n≥11 animals/group; Fig. 2A,C show inhibitory response at higher doses. — Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption

Hypoxic retinal area at P17 and P21: Hypoxyprobe staining; Fig. 2D: p<0.01, n≥9 animals/group; no exact percent reduction digitized. — Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption

Moderate-dose MDL 28170 · Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption

Higher-dose limitation · Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 88191-84-8
Applications Calpain Inhibitor III
Formula C22H26N2O4
Molecular Weight 382.45
Synonyms Calpain Inhibitor III
SMILES
CC(C)C(C(=O)NC(CC1=CC=CC=C1)C=O)NC(=O)OCC2=CC=CC=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 69 mg/mL (180.41 mM)
Water Insoluble
Ethanol 9 mg/mL (23.53 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MDL 28170 Research References

  1. [1] Hoang MV, Smith LE, Senger DR. Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion. Biochimica et biophysica acta (2011). PMID: 20804843 DOI: 10.1016/j.bbadis.2010.08.008 Source material
  2. [2] Thompson SN, Carrico KM, Mustafa AG, et al. A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model. Journal of neurotrauma (2010). PMID: 20874056 DOI: 10.1089/neu.2010.1474 Source material
  3. [3] Ma M, Li L, Wang X, et al. Short-duration treatment with the calpain inhibitor MDL-28170 does not protect axonal transport in an in vivo model of traumatic axonal injury. Journal of neurotrauma (2012). PMID: 22077394 DOI: 10.1089/neu.2011.2060 Source material

Publications

1 publication citing this product

  1. Barker BS, .et al. , Neuroscience, 2019, Nov 26. pii: S0306-4522(19)30796-1 PMID: 31783100

Added to your cart

View Cart Checkout
Loading...